BiotechTube
Calosyn Pharma

Calosyn Pharma

San Diego, United States· Est.
calosyn.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

Calosyn Pharma is advancing a novel, sustained-release injectable therapy, CAL-05CR, for moderate to severe osteoarthritis pain. The drug candidate is a reformulation of verapamil, a calcium channel blocker, based on foundational research linking aberrant calcium signaling to disease pathology. The company has generated promising human data and is positioned to advance into Phase 2 clinical trials, targeting a large market with significant unmet need. Calosyn is a private company led by a team with deep orthopedic clinical and pharmaceutical development expertise.

OsteoarthritisPain

Technology Platform

Sustained-release microsphere drug delivery system for intra-articular injection, targeting aberrant calcium channel signaling in osteoarthritic synovium.

Funding History

1
Total raised:$3M
Seed$3M

Opportunities

The global osteoarthritis market is large and growing, with a critical unmet need for disease-modifying therapies that offer sustained pain relief.
CAL-05CR's novel mechanism (calcium channel blockade) and delivery system position it uniquely in a competitive landscape dominated by palliative care.
Positive Phase 2 data could enable a high-value partnership or acquisition by a larger pharmaceutical company.

Risk Factors

The company faces significant clinical development risk in translating early human data into successful controlled trials.
As a pre-revenue, private company, it is highly dependent on securing funding to advance its program.
There is also formulation/manufacturing risk and competition from other entities pursuing disease-modifying OA drugs.

Competitive Landscape

The osteoarthritis treatment market is crowded with palliative options (NSAIDs, steroids, hyaluronic acid) but has few approved disease-modifying agents. Calosyn competes with other biotechs and pharma companies developing novel injectables, small molecules, and biologics aimed at pain and structure modification. Its differentiation lies in the repurposing of verapamil via a proprietary sustained-release delivery system.

More companies in Drug Delivery & Formulation →More companies in United States →